SK572003A3 - Crystalline therapeutic agent - Google Patents

Crystalline therapeutic agent Download PDF

Info

Publication number
SK572003A3
SK572003A3 SK57-2003A SK572003A SK572003A3 SK 572003 A3 SK572003 A3 SK 572003A3 SK 572003 A SK572003 A SK 572003A SK 572003 A3 SK572003 A3 SK 572003A3
Authority
SK
Slovakia
Prior art keywords
ethyl
methoxyethyl
ethoxy
compound
mol
Prior art date
Application number
SK57-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Laurence James Harris
Richard Anthony Storey
Albert Shaw Wood
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0018656A external-priority patent/GB0018656D0/en
Priority claimed from GB0106464A external-priority patent/GB0106464D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of SK572003A3 publication Critical patent/SK572003A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
SK57-2003A 2000-07-28 2001-07-18 Crystalline therapeutic agent SK572003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0018656A GB0018656D0 (en) 2000-07-28 2000-07-28 Pharmaceutically active compounds
GB0106464A GB0106464D0 (en) 2001-03-15 2001-03-15 Crystalline therapeutic agent
PCT/IB2001/001280 WO2002010171A1 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Publications (1)

Publication Number Publication Date
SK572003A3 true SK572003A3 (en) 2004-05-04

Family

ID=26244756

Family Applications (1)

Application Number Title Priority Date Filing Date
SK57-2003A SK572003A3 (en) 2000-07-28 2001-07-18 Crystalline therapeutic agent

Country Status (46)

Country Link
EP (1) EP1305314B1 (es)
JP (1) JP2004505087A (es)
KR (1) KR100457937B1 (es)
CN (1) CN1207297C (es)
AP (1) AP1400A (es)
AR (1) AR032628A1 (es)
AT (1) ATE286901T1 (es)
AU (2) AU7269001A (es)
BG (1) BG107266A (es)
BR (1) BR0112734A (es)
CA (1) CA2417264C (es)
CZ (1) CZ2003126A3 (es)
DE (1) DE60108398T2 (es)
DO (1) DOP2001000217A (es)
DZ (1) DZ3364A1 (es)
EA (1) EA004681B1 (es)
EC (1) ECSP034454A (es)
EE (1) EE200300045A (es)
ES (1) ES2231521T3 (es)
GE (1) GEP20053494B (es)
HK (1) HK1055954A1 (es)
HR (1) HRP20030061A2 (es)
HU (1) HUP0302982A3 (es)
IL (1) IL153226A0 (es)
IN (1) IN2002MU01649A (es)
IS (1) IS6626A (es)
MA (1) MA26931A1 (es)
MX (1) MX233602B (es)
MY (1) MY117831A (es)
NO (1) NO324220B1 (es)
NZ (1) NZ523226A (es)
OA (1) OA12337A (es)
PA (1) PA8523501A1 (es)
PE (1) PE20020277A1 (es)
PH (1) PH12001001922B1 (es)
PL (1) PL365133A1 (es)
PT (1) PT1305314E (es)
SK (1) SK572003A3 (es)
SV (1) SV2001000570A (es)
TN (1) TNSN01112A1 (es)
TW (1) TWI285643B (es)
UA (1) UA72631C2 (es)
UY (1) UY26854A1 (es)
WO (1) WO2002010171A1 (es)
YU (1) YU4703A (es)
ZA (1) ZA200301457B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
EP1620437B1 (en) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
EA012577B1 (ru) 2005-05-12 2009-10-30 Пфайзер Инк. БЕЗВОДНЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[1-(2-ЭТОКСИЭТИЛ)-5-(N-ЭТИЛ-N-МЕТИЛАМИНО)-7-(4-МЕТИЛПИРИДИН-2-ИЛАМИНО)-1Н-ПИРАЗОЛО[4,3-d]ПИРИМИДИН-3-КАРБОНИЛ]МЕТАНСУЛЬФОНАМИДА

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1073658E (pt) * 1998-04-20 2003-12-31 Pfizer Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them

Also Published As

Publication number Publication date
PA8523501A1 (es) 2002-10-24
AP2001002234A0 (en) 2001-09-30
DZ3364A1 (fr) 2002-02-07
TNSN01112A1 (fr) 2005-11-10
CN1444585A (zh) 2003-09-24
AP1400A (en) 2005-04-28
NZ523226A (en) 2003-07-25
IL153226A0 (en) 2003-07-06
WO2002010171A1 (en) 2002-02-07
MY117831A (en) 2004-08-30
MX233602B (es) 2006-01-10
UA72631C2 (uk) 2005-03-15
BG107266A (bg) 2003-07-31
MXPA03000856A (es) 2003-06-06
GEP20053494B (en) 2005-04-25
UY26854A1 (es) 2002-02-28
JP2004505087A (ja) 2004-02-19
TWI285643B (en) 2007-08-21
AU2001272690B2 (en) 2005-12-08
EP1305314B1 (en) 2005-01-12
EE200300045A (et) 2004-12-15
PE20020277A1 (es) 2002-05-11
DOP2001000217A (es) 2002-10-30
EA200300079A1 (ru) 2003-06-26
HRP20030061A2 (en) 2003-04-30
OA12337A (en) 2006-05-15
PT1305314E (pt) 2005-04-29
CA2417264A1 (en) 2002-02-07
CN1207297C (zh) 2005-06-22
CA2417264C (en) 2007-06-12
PH12001001922B1 (en) 2006-11-21
IN2002MU01649A (es) 2004-12-11
YU4703A (sh) 2006-01-16
BR0112734A (pt) 2004-08-10
ATE286901T1 (de) 2005-01-15
AR032628A1 (es) 2003-11-19
EA004681B1 (ru) 2004-06-24
NO20030416D0 (no) 2003-01-27
DE60108398D1 (de) 2005-02-17
CZ2003126A3 (cs) 2004-02-18
IS6626A (is) 2002-11-18
NO324220B1 (no) 2007-09-10
AU7269001A (en) 2002-02-13
HUP0302982A2 (hu) 2003-12-29
NO20030416L (no) 2003-02-05
ZA200301457B (en) 2004-04-28
HK1055954A1 (en) 2004-01-30
EP1305314A1 (en) 2003-05-02
HUP0302982A3 (en) 2005-01-28
MA26931A1 (fr) 2004-12-20
ES2231521T3 (es) 2005-05-16
KR100457937B1 (ko) 2004-11-20
ECSP034454A (es) 2003-03-10
SV2001000570A (es) 2002-09-03
DE60108398T2 (de) 2005-12-22
KR20030016430A (ko) 2003-02-26
PL365133A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
DE60016615T2 (de) Pyrazolo[4,3-d]pyrimidinderivate
DE60202134T2 (de) Zyklische guanosine 3',5'-monophosphate phosphodiesterase inhibitoren
JP3721023B2 (ja) 性的機能障害の治療用のピラゾロピリミジノンcGMPPDE5阻害剤
SK4562002A3 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
RU2548363C2 (ru) СЕЛЕКТИВНЫЕ ИНГИБИТОРЫ Haspin киназы
CA2287562A1 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
AU2012363094A1 (en) Methods and compositions for treating Parkinson's disease
CA2767992C (en) 2 - [[[2 -[(hydroxyacetyl) amino]- 4 -pyridinyl] methyl] thio]- n -[4 - (trifluoromethoxy) phenyl]- 3 -pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
WO2004108726A1 (fr) Derives phenyl-5,7-dialalkyl-3,7-dihydropyrrol[2,3-d]pyrimidine-4-one substitues en position 2, leur preparation et leur utilisation en pharmacie
SK572003A3 (en) Crystalline therapeutic agent
US6420557B1 (en) Crystalline therapeutic agent
US6350751B1 (en) Therapeutic agents
EP1220855B1 (en) Anhydrous salt
AU2001272690A1 (en) Crystalline therapeutic agent
US20040235857A1 (en) Crystalline therapeutic agent

Legal Events

Date Code Title Description
FC9A Refused patent application